title: Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs.
abstract: Like most pharmaceutical agents, vitamin D analogs are subject to hepatic metabolism by a variety of cytochrome P450 (CYP)-based systems. Metabolism can involve activation as well as inactivation of the vitamin D analog and one of the more successful families includes the 1alpha-hydroxyvitamin D prodrugs (1alpha-OH-D2, 1alpha-OH-D3, 1alpha-OH-D4, 1alpha-OH-D5), that all require a step of activation. Some of these prodrugs are in use or clinical trial because they have a therapeutic advantage over calcitriol. However, the nature of the activation of these molecules is poorly understood, particularly with regard to the CYP isoform involved. Various transfected CYPs and hepatic cell lines combined with tandem LC-MS analysis were used to investigate the metabolism of a spectrum of vitamin D analogs, including 1alpha-OH-Ds and the topical analog, calcipotriol. In the case of the 1alpha-OH-Ds, evidence was found of multiple sites of side-chain hydroxylation consistent with the generation of more than one active form. The potential involvement of CYP27A and other putative 25-hydroxylases in 1alpha-OH-D activation was also shown, as well as the potential for CYP24 activation and inactivation. In the case of calcipotriol, the respective roles of non-vitamin D-related CYPs and CYP24 in the catabolism of this anti-psoriatic drug were dissected out using cell lines with or without CYP24 expression, allowing us to demonstrate the potential contribution of CYP24 to "vitamin D resistance". The implications of hepatic metabolism in the context of other facets thought to play a role in the mechanism of action of anticancer and antiproliferative vitamin D analogs are discussed.
authors.affiliation: Department of Biochemistry, Queen's University, Kingston, ON, Canada. gj1@post.queensu.ca
authors.forename: Glenville
authors.initials: G
authors.lastname: Jones
authors.forename: Valarie
authors.initials: V
authors.lastname: Byford
authors.forename: Shelly
authors.initials: S
authors.lastname: West
authors.forename: Sonoko
authors.initials: S
authors.lastname: Masuda
authors.forename: George
authors.initials: G
authors.lastname: Ibrahim
authors.forename: Martin
authors.initials: M
authors.lastname: Kaufmann
authors.forename: Joyce C
authors.initials: JC
authors.lastname: Knutson
authors.forename: Stephen
authors.initials: S
authors.lastname: Strugnell
authors.forename: Rajendra
authors.initials: R
authors.lastname: Mehta
mesh_terms: D000818:Animals; D001711:Biotransformation; D002117:Calcitriol / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D002460:Cell Line; D045744:Cell Line, Tumor; D053493:Cholestanetriol 26-Monooxygenase; D002853:Chromatography, Liquid; D006224:Cricetinae; D006801:Humans; D006887:Hydroxycholecalciferols / Q000378:metabolism / Q000493:pharmacokinetics; D008099:Liver / Q000201:enzymology / Q000378:metabolism*; D013058:Mass Spectrometry; D011355:Prodrugs / Q000493:pharmacokinetics*; D013250:Steroid Hydroxylases / Q000378:metabolism; D014807:Vitamin D / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D065668:Vitamin D3 24-Hydroxylase
chemical_list: C103958:1-hydroxyvitamin D5; D006887:Hydroxycholecalciferols; D011355:Prodrugs; D014807:Vitamin D; C055085:calcipotriene; D013250:Steroid Hydroxylases; C506831:CYP27A1 protein, human; D053493:Cholestanetriol 26-Monooxygenase; D065668:Vitamin D3 24-Hydroxylase; D002117:Calcitriol